Background

24:I[63208,["8920","static/chunks/8920-efbff8517d590b7e.js","9097","static/chunks/9097-7e60ff382fede0de.js","5914","static/chunks/5914-356082358a498a0b.js","9903","static/chunks/9903-11222066602aad8e.js","5438","static/chunks/5438-cfc6cd3ec63ed58c.js","3851","static/chunks/3851-d9d99b9df58ccefb.js","4621","static/chunks/4621-60797c2425663d2a.js","6871","static/chunks/6871-85cb03c97585f46a.js","6736","static/chunks/6736-932312a004c99faf.js","4550","static/chunks/4550-0bf059e3050c08b3.js","688","static/chunks/688-a6a2ac7bff269cd3.js","3984","static/chunks/3984-063c0b62f32133c7.js","7038","static/chunks/7038-4f87670d4e55ef18.js","9039","static/chunks/9039-75366c62dc7d0d0e.js","4563","static/chunks/4563-ad980d1babbf7b0b.js","6761","static/chunks/6761-0c10d1446de7ae1c.js","744","static/chunks/744-1e76229abb9e297b.js","7342","static/chunks/7342-1586df78600bf911.js","3617","static/chunks/3617-1f62a097637f4747.js","5895","static/chunks/5895-caa6c774914eb108.js","7481","static/chunks/7481-3b84c503a2ebfb3f.js","3668","static/chunks/3668-7dab69e4121c33af.js","39","static/chunks/39-e93a27d0920e6d92.js","2881","static/chunks/2881-445cc2384af2c6f9.js","2364","static/chunks/2364-e83d52fb21729d99.js","3208","static/chunks/3208-e65462d166bd3688.js","7582","static/chunks/app/toc/%5Btla%5D/%5Bvolume%5D/%5Bissue%5D/page-694a0e465c2c1334.js"],"default"] 25:T512, Background

Mycophenolate mofetil (MMF) is a widely used immune suppressant. It is derived from mycophenolic acid, which was once used as an anti-psoriatic agent, but was discontinued due to adverse effects. MMF has a lower incidence of adverse effects and could be a therapeutic option for psoriasis patients.

Objective

To review the current literature on the safety and efficacy of MMF as a treatment for psoriasis.

Methods

We searched PubMed and the Cochrane Library using the search terms “psoriasis” and “mycophenolate mofetil” for articles evaluating the efficacy and safety of MMF in patients with psoriasis.

Results

Studies showed that MMF reduced disease severity and had minimal adverse effects. However, most studies had a small sample size.

Conclusions

There is available evidence supporting MMF as a well-tolerated, effective treatment of psoriasis. Further studies in the form of randomized control trials should be considered to confirm these limited data.

26:T4b3,

Psoriasis is a common, chronic inflammatory skin disease that has been increasingly associated with major systemic effects. Dose-response relationships between objectively determined psoriasis severity and increased comorbid disease burden were recently demonstrated in a large, population-based study. Significant associations with cardiovascular disease, diabetes mellitus and its complications, chronic kidney disease, chronic pulmonary disease, mild liver disease, peptic ulcer disease, and rheumatologic disease were shown in patients with increasingly severe psoriasis. Future research should confirm novel comorbid disease associations and investigate the impact of psoriasis therapy on comorbid disease outcomes. For now, dermatologists, as well as primary care physicians, medical specialists, and patients suffering from moderate-to-severe psoriasis, should be aware of these associations to improve multi-disciplinary approaches for screening, monitoring, and treatment of comorbid diseases. Future evidence-based guidelines should incorporate strategies on how clinicians should address cardiovascular and other comorbid diseases, particularly for patients with more severe psoriasis.

27:T5f7,